George Golumbeski has more than 30 years of experience in the biotechnology industry. He has a long history of forging collaborations with companies engaged in “cutting edge” science. Currently he is dedicated to working to develop young companies. He is a partner at DROIA Ventures. He currently serves on the Board of Directors of Carrick Therapeutics, Sage Therapeutics, and MorphoSys. George was most recently Executive Vice President of Business Development for Celgene, where he was responsible for forging collaborations with biotechnology companies seeking to bring breakthrough medications to people suffering from cancer and chronic inflammation. He holds a PhD in Genetics from the University of Wisconsin-Madison, and conducted his post-doctoral research in molecular biology at the University of Colorado-Boulder. George holds a bachelor’s degree in biology from the University of Virginia
